Pakistan Pharmaceutical: Listed Pharma Sector Analysis 3QFY25; Deregulation improved sales and margins - By Topline Research
May 9 2025
Topline Securities
- Pakistan listed pharmaceuticals sector’s earnings were up by 83% YoY to Rs8.0bn in 3QFY25. This jump in profitability is primarily attributed to higher net sales, improved gross margins, and a decline in finance cost.
- Net sales increased by 12% YoY to Rs85.5bn in 3QFY25, primarily driven by an increase in drug prices following the deregulation of non-essential drugs in Feb-2024. Haleon, ABOT, FEROZ, HPL, and AGP led the sector, showing strong sales growth in absolute terms.
- This price increase led to an improvement in gross margins, rising to 39% in 3QFY25 from 31% in 3QFY24. Additionally, the recent decline in raw material prices for many drugs and the stable currency further contributed to the increase in gross margins. AGP recorded highest gross margins of 58% in 3QFY25.